Pasithea Therapeutics (KTTA) Competitors

$0.79 +0.01 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.03 (+4.26%)

As of 08:00 PM Eastern

KTTA vs. CTOR, EXOZ, BHST, ATYR, and JATT

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Citius Oncology (CTOR), eXoZymes (EXOZ), BioHarvest Sciences (BHST), aTyr Pharma (ATYR), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.

How does Pasithea Therapeutics compare to Citius Oncology?

Pasithea Therapeutics (NASDAQ:KTTA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Citius Oncology had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Citius Oncology and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat Citius Oncology's score of 0.79 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
Citius Oncology	Positive

Pasithea Therapeutics has higher earnings, but lower revenue than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A
Citius Oncology	$3.94M	22.03	-$24.76M	-$0.31	N/A

Pasithea Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 277.74%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 509.57%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.56, indicating that its share price is 256% more volatile than the broader market.

Citius Oncology's return on equity of -55.19% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-85.48%	-77.42%
Citius Oncology	N/A	-55.19%	-23.99%

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 7.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Citius Oncology beats Pasithea Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to eXoZymes?

Pasithea Therapeutics (NASDAQ:KTTA) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 277.74%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pasithea Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, indicating that its share price is 185% more volatile than the broader market.

In the previous week, eXoZymes had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat eXoZymes' score of 0.62 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
eXoZymes	Positive

eXoZymes has higher revenue and earnings than Pasithea Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A
eXoZymes	$70K	1,163.58	-$9.16M	-$1.08	N/A

23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pasithea Therapeutics' return on equity of -85.48% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-85.48%	-77.42%
eXoZymes	N/A	-147.18%	-104.98%

Summary

Pasithea Therapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to BioHarvest Sciences?

Pasithea Therapeutics (NASDAQ:KTTA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

BioHarvest Sciences has higher revenue and earnings than Pasithea Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A
BioHarvest Sciences	$34.51M	2.37	-$11.14M	-$0.61	N/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pasithea Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.27%. Pasithea Therapeutics' return on equity of -85.48% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-85.48%	-77.42%
BioHarvest Sciences	-32.27%	-136.42%	-27.92%

In the previous week, BioHarvest Sciences had 11 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 12 mentions for BioHarvest Sciences and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat BioHarvest Sciences' score of 0.36 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
BioHarvest Sciences	Neutral

Pasithea Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 277.74%. BioHarvest Sciences has a consensus price target of $10.00, suggesting a potential upside of 140.38%. Given Pasithea Therapeutics' higher probable upside, research analysts clearly believe Pasithea Therapeutics is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pasithea Therapeutics and BioHarvest Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, aTyr Pharma had 8 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 9 mentions for aTyr Pharma and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat aTyr Pharma's score of 0.15 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
aTyr Pharma	Neutral
Pasithea Therapeutics	Very Positive

Pasithea Therapeutics' return on equity of -85.48% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-99.87%	-74.41%
Pasithea Therapeutics	N/A	-85.48%	-77.42%

Pasithea Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	288.94	-$74.12M	-$0.79	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A

aTyr Pharma currently has a consensus target price of $25.67, suggesting a potential upside of 4,484.15%. Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 277.74%. Given aTyr Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe aTyr Pharma is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

aTyr Pharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Summary

aTyr Pharma beats Pasithea Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Pasithea Therapeutics compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 277.74%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Pasithea Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Pasithea Therapeutics and 0 mentions for JATT Acquisition. Pasithea Therapeutics' average media sentiment score of 1.87 beat JATT Acquisition's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Pasithea Therapeutics	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A

JATT Acquisition's return on equity of -49.58% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Pasithea Therapeutics	N/A	-85.48%	-77.42%

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

JATT Acquisition and Pasithea Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.58M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.22	18.47	20.90	25.61
Price / Sales	N/A	295.31	549.47	78.77
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.33	6.93	9.93	6.96
Net Income	-$20.43M	$24.11M	$3.55B	$333.52M
7 Day Performance	-5.45%	0.08%	-0.33%	0.45%
1 Month Performance	0.53%	0.84%	1.34%	4.06%
1 Year Performance	-16.86%	78.10%	41.10%	36.24%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.7025 of 5 stars	$0.79 +1.2%	$3.00 +277.7%	-8.7%	$19.58M	N/A	N/A	3	Positive News Upcoming Earnings
CTOR Citius Oncology	2.5637 of 5 stars	$0.91 -5.0%	$6.00 +559.8%	+7.7%	$84.47M	N/A	N/A	N/A	Upcoming Earnings
EXOZ eXoZymes	0.2384 of 5 stars	$9.90 +0.1%	N/A	-32.2%	$83.84M	$70K	N/A	29	Earnings Report
BHST BioHarvest Sciences	2.8704 of 5 stars	$4.20 -0.2%	$10.00 +138.1%	-38.7%	$82.58M	$34.51M	N/A	N/A	Trending News Earnings Report
ATYR aTyr Pharma	2.322 of 5 stars	$1.04 +22.9%	$25.67 +2,379.9%	-88.0%	$82.58M	$190K	N/A	53	News Coverage Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. CTOR, EXOZ, BHST, ATYR, and JATT

How does Pasithea Therapeutics compare to Citius Oncology?

Summary

How does Pasithea Therapeutics compare to eXoZymes?

Summary

How does Pasithea Therapeutics compare to BioHarvest Sciences?

Summary

How does Pasithea Therapeutics compare to aTyr Pharma?

Summary

How does Pasithea Therapeutics compare to JATT Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. CTOR, EXOZ, BHST, ATYR, and JATT

How does Pasithea Therapeutics compare to Citius Oncology?

Does the media refer more to KTTA or CTOR?

Which has stronger earnings and valuation, KTTA or CTOR?

Do analysts prefer KTTA or CTOR?

Which has more risk & volatility, KTTA or CTOR?

Is KTTA or CTOR more profitable?

Do insiders and institutionals have more ownership in KTTA or CTOR?

Summary

How does Pasithea Therapeutics compare to eXoZymes?

Do analysts rate KTTA or EXOZ?

Which has more volatility & risk, KTTA or EXOZ?

Does the media prefer KTTA or EXOZ?

Which has better earnings and valuation, KTTA or EXOZ?

Do insiders & institutionals have more ownership in KTTA or EXOZ?

Is KTTA or EXOZ more profitable?

Summary

How does Pasithea Therapeutics compare to BioHarvest Sciences?

Which has preferable valuation & earnings, KTTA or BHST?

Do insiders & institutionals hold more shares of KTTA or BHST?

Is KTTA or BHST more profitable?

Does the media prefer KTTA or BHST?

Which has more volatility and risk, KTTA or BHST?

Do analysts prefer KTTA or BHST?

Summary

How does Pasithea Therapeutics compare to aTyr Pharma?

Does the media prefer ATYR or KTTA?

Is ATYR or KTTA more profitable?

Which has stronger earnings & valuation, ATYR or KTTA?

Do analysts recommend ATYR or KTTA?

Do insiders & institutionals hold more shares of ATYR or KTTA?

Which has more risk & volatility, ATYR or KTTA?

Summary

How does Pasithea Therapeutics compare to JATT Acquisition?

Do analysts prefer JATT or KTTA?

Does the media refer more to JATT or KTTA?

Which has higher earnings and valuation, JATT or KTTA?

Is JATT or KTTA more profitable?

Do insiders & institutionals believe in JATT or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools